Author:
Lad Deepesh P.,Malhotra Pankaj,Khadwal Alka,Prakash Gaurav,Jain Arihant,Varma Subhash
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Imbruvica® (ibrutinib) [package insert] (2017) Horsham, PA: Janssen Biotech, Inc. https://www.imbruvica.com/docs/librariesprovider7/default-document-library/prescribing_information.pdf . Accessed 5 June 2018
2. Gayko U, Fung M, Clow F, Sun S, Faust E, Price S et al (2015) Development of the Bruton’s tyrosine kinase inhibitor ibrutinib for B cell malignancies. Ann N Y Acad Sci 1358:82–94
3. O’Brien SM, Furman RR, Coutre SE, Flinn IW, Burger J, Blum K, Sharman J, Wierda WG, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC (2016) Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood 128:233
4. Ghia P, Cuneo A (2016) Ibrutinib in the real world patient: many lights and some shades. Haematologica 101(12):1448–1450
5. Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P et al (2018) Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol 180(5):666–679
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献